This Article Full Text (PDF) All Versions of this Article: 0897190008330197v1 22/5/446    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Kemp, D. W. Articles by Brown, J. N. Social Bookmarking                         What's this?

Recent Advances in Pharmacotherapy

From the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill (DWK); and Durham VA Medical Center, Durham (DWK, JNB), North Carolina.

Correspondence: Debra W. Kemp, PharmD, BCPS, UNC Eshelman School of Pharmacy, Division of Pharmacy Practice and Experiential Education, CB#7360, Chapel Hill, NC 27599; e-mail: debra.kemp{at}va.gov.

Many unique and clinically important medications were approved by the Food and Drug Administration from December 2007 through May 2008 for various conditions encountered in an internal medicine setting. These new treatments dramatically vary in their targeted body system and include agents for the cardiovascular system (nebivolol), central nervous system (desvenlafaxine), gastrointestinal tract (certolizumab, methylnaltrexone, and alvimopan), immunological function (etravirine), and metabolic function (sapropterin). This article discusses medications by their respective body system. Each review is comprised of an overview of the Food and Drug Administration–approved indication and the drug’s role in treatment of that disease state. Current dosing guidance, clinical efficacy and clinically relevant adverse drug reactions, drug interactions, contraindications, and precautions are also presented. This review is designed to focus on the new molecular entities and biological approvals clinicians may potentially encounter in an internal medicine practice.

Key Words: internal medicine • pharmacotherapy update • new drug review • medication approval

This version was published on October 1, 2009

Journal of Pharmacy Practice, Vol. 22, No. 5, 446-466 (2009)
DOI: 10.1177/0897190008330197


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?